Vaccine (Adenoviral vector) · Immune activation, directed at anthrax PA · developed by Emergent BioSolutions
Ad4-PA-1 is an adenovirus serotype 4 vector vaccine encoding anthrax protective antigen (PA). It is administered as a primary immunization followed by an AVA boost, studied for prevention of anthrax infection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01979406 | Phase 1 | Anthrax Infection | Completed | EBS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Anthrax Infection
Updated Oct 3, 2026. Something wrong or missing? Report it on the EBS page.
See EBS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
EBS catalysts and pipeline →